Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESENDO for Critical Limb Ischemia
NCT00721006Phase 2Completed
- Sponsor
- TCA Cellular Therapy
- Start
- Jun 2008
- Primary completion
- Aug 2010
- Modality
- Bone Marrow HSCs, Adipose-derived MSCs, Patient-derived iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of Mesendo in critical limb ischemia (CLI), sponsored by TCA Cellular Therapy. Started Jun 2008; status: completed.
02
Drugs
Mesendo
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00721006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00721006.